NCT03072134View on ClinicalTrials.gov

Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

April 6, 2020

Study Completion Date

July 1, 2021

Conditions
GliomaAnaplastic AstrocytomaAnaplastic OligodendrogliomaAnaplastic OligoastrocytomaGlioblastoma MultiformeAstrocytoma, Grade IIIAstrocytoma, Grade IVBrain Cancer
Interventions
BIOLOGICAL

Neural stem cells loaded with an oncolytic adenovirus

The primary objectives are to evaluate the safety of the combined therapy and determine the maximum tolerated dose (MTD) for a future Phase II study.

Trial Locations (2)

60611

Northwestern Memorial Hospital, Chicago

91010

City of Hope, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT03072134 - Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | Biotech Hunter | Biotech Hunter